Core Viewpoint - The regulatory letter issued by the Shenzhen Stock Exchange highlights violations by Tibet Duorui Pharmaceutical Co., Ltd. regarding improper use of raised funds and failure to disclose information [1][8]. Group 1: Regulatory Violations - Tibet Duorui Pharmaceutical used 73 million yuan of raised funds to purchase a 7-day notice deposit from Hengfeng Bank without fulfilling information disclosure obligations [1][7]. - The company violated the Shenzhen Stock Exchange's "Rules for Listing of Stocks on the Growth Enterprise Market (Revised December 2020)" Articles 1.4 and 5.1.1 [1][8]. - The former board secretary, Jin Fen, failed to perform due diligence and is held responsible for the violations under the same rules [1][8]. Group 2: Financial Information - Tibet Duorui Pharmaceutical raised a total of 545 million yuan, with a net amount of 482 million yuan after deducting issuance costs [4][5]. - The final net amount raised exceeded the original plan by 87.67 million yuan, which was initially set at 394 million yuan for various projects [5]. - The company went public on September 29, 2021, issuing 20 million shares at a price of 27.27 yuan per share, representing 25% of the total share capital post-issuance [1][5]. Group 3: Listing and Performance - On its first trading day, the stock reached a peak price of 54.55 yuan, which remains the highest price to date [2]. - Currently, the stock is in a state of decline, having broken its initial offering price [3]. Group 4: Underwriting and Fees - The underwriting fees for the public offering amounted to 63.35 million yuan, with the sponsor, CITIC Securities, receiving a total of 39.60 million yuan [6][7].
破发股多瑞医药收监管函 上市募5.45亿中信证券保荐